Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.

Cho JH, Sorensen SF, Choi YL, Feng Y, Kim TE, Choi H, Georgsen JB, Dolled-Filhart M, Emancipator K, Meldgaard P, Sun JM, Kim HK, Choi YS, Shim YM, Zhou W, Hager H, Kim J.

Clin Lung Cancer. 2017 Nov;18(6):e473-e479. doi: 10.1016/j.cllc.2017.04.008. Epub 2017 Apr 24.

PMID:
28669849
2.

Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer.

Cho JH, Zhou W, Choi YL, Sun JM, Choi H, Kim TE, Dolled-Filhart M, Emancipator K, Rutkowski MA, Kim J.

Cancer Res Treat. 2018 Jan;50(1):95-102. doi: 10.4143/crt.2016.591. Epub 2017 Mar 17.

3.

PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy.

Steiniche T, Vestergaard Danielsen A, Wang Z, Feng Y, Switten Nielsen P, Bastholt L, Schmidt H, Svane IM, Dolled-Filhart M, Emancipator K, Weiner R, Busch-Sørensen M, Zhou W.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):e319-e321. doi: 10.1111/jdv.14106. Epub 2017 Jan 31. No abstract available.

PMID:
28045203
4.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

5.

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.

Dolled-Filhart M, Locke D, Murphy T, Lynch F, Yearley JH, Frisman D, Pierce R, Weiner R, Wu D, Emancipator K.

Arch Pathol Lab Med. 2016 Nov;140(11):1259-1266.

PMID:
27788043
6.

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY.

J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.

7.

Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.

Dolled-Filhart M, Roach C, Toland G, Stanforth D, Jansson M, Lubiniecki GM, Ponto G, Emancipator K.

Arch Pathol Lab Med. 2016 Aug 23. [Epub ahead of print]

PMID:
27552095
8.

[Letter to the Editor] The need for improved education and training in research antibody usage and validation practices.

Freedman LP, Gibson MC, Bradbury AR, Buchberg AM, Davis D, Dolled-Filhart MP, Lund-Johansen F, Rimm DL.

Biotechniques. 2016 Jul 1;61(1):16-8. doi: 10.2144/000114431. eCollection 2016.

9.

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.

Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K.

Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7. doi: 10.1097/PAI.0000000000000408.

10.

Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.

Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, Dolled-Filhart M, Emancipator K, Wu D, Weiner R, Frisman D, Kim HK, Choi YS, Shim YM, Kim J.

J Thorac Oncol. 2016 Jul;11(7):1003-11. doi: 10.1016/j.jtho.2016.04.007. Epub 2016 Apr 18.

11.

PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.

Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H.

Transl Oncol. 2016 Feb;9(1):64-69. doi: 10.1016/j.tranon.2016.01.003.

12.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB.

Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.

PMID:
26712084
13.

Pembrolizumab for the treatment of non-small-cell lung cancer.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.

N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.

14.

Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology.

O'Shannessy DJ, Gustavson M, Chandrasekaran LK, Dolled-Filhart M, Somers EB.

Biomark Med. 2013 Dec;7(6):933-46. doi: 10.2217/bmm.13.85.

PMID:
24266829
15.

Tissue microarrays: leaping the gap between research and clinical adoption.

Gustavson MD, Rimm DL, Dolled-Filhart M.

Per Med. 2013 Jul;10(5):441-451. doi: 10.2217/pme.13.42.

PMID:
29758838
16.

Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development.

Dolled-Filhart MP, Gustavson MD.

Expert Opin Med Diagn. 2012 Nov;6(6):569-83. doi: 10.1517/17530059.2012.708336. Epub 2012 Aug 6.

PMID:
23480838
17.

Computational and bioinformatics frameworks for next-generation whole exome and genome sequencing.

Dolled-Filhart MP, Lee M Jr, Ou-Yang CW, Haraksingh RR, Lin JC.

ScientificWorldJournal. 2013;2013:730210. doi: 10.1155/2013/730210. Epub 2013 Jan 13. Review.

18.

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11. doi: 10.1016/j.ijrobp.2012.10.008. Epub 2012 Nov 22.

19.

Personalizing rare disease research: how genomics is revolutionizing the diagnosis and treatment of rare disease.

Dolled-Filhart MP, Lordemann A, Dahl W, Haraksingh RR, Ou-Yang CW, Lin JC.

Per Med. 2012 Nov;9(8):805-819. doi: 10.2217/pme.12.97.

PMID:
29776237
20.

Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary: cutting edge or already obsolete?

Dolled-Filhart MP, Rimm DL.

Cancer Cytopathol. 2013 Mar;121(3):129-35. doi: 10.1002/cncy.21228. Epub 2012 Aug 23. No abstract available.

21.

Company Profile: HistoRx: tissue-based diagnostic solutions for personalized medicine.

Dolled-Filhart M, Romeo E, Adams K, Davis W, Gustavson M.

Per Med. 2012 Mar;9(2):185-190. doi: 10.2217/pme.12.4.

PMID:
29758817
22.

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.

Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN.

Br J Cancer. 2011 Jan 4;104(1):68-74. doi: 10.1038/sj.bjc.6605972. Epub 2010 Nov 23. Retraction in: Br J Cancer. 2012 Dec 4;107(12):2024.

23.

Automated analysis of tissue microarrays.

Dolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J.

Methods Mol Biol. 2010;664:151-62. doi: 10.1007/978-1-60761-806-5_15.

PMID:
20690061
24.

Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.

Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV.

Clin Cancer Res. 2010 Sep 15;16(18):4654-65. doi: 10.1158/1078-0432.CCR-10-0089. Epub 2010 Jul 29. Retraction in: Clin Cancer Res. 2014 Jun 15;20(12):3358.

25.

The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress.

Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A, Manning G, Abraham RT, Hunter T.

Mol Cell. 2009 Aug 28;35(4):442-53. doi: 10.1016/j.molcel.2009.06.030.

26.

Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation.

Emerson JW, Dolled-Filhart M, Harris L, Rimm DL, Tuck DP.

Cancer Inform. 2009;7:29-40. Epub 2008 Dec 23.

27.

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.

Anderson WF, Luo S, Chatterjee N, Rosenberg PS, Matsuno RK, Goodman MT, Hernandez BY, Reichman M, Dolled-Filhart MP, O'Regan RM, Garcia-Closas M, Perou CM, Jatoi I, Cartun RW, Sherman ME.

Breast Cancer Res Treat. 2009 Jan;113(1):189-96. doi: 10.1007/s10549-008-9918-3. Epub 2008 Feb 7.

28.

Classification of breast cancer using genetic algorithms and tissue microarrays.

Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL.

Clin Cancer Res. 2006 Nov 1;12(21):6459-68.

29.

Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome.

Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL.

Cancer Res. 2006 May 15;66(10):5487-94.

30.

Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.

McCabe A, Dolled-Filhart M, Camp RL, Rimm DL.

J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15.

PMID:
16368942
31.

Quantitative in situ cancer proteomics: molecular pathology comes of age with automated tissue microarray analysis.

Dolled-Filhart MP, Rimm DL, Stroobant P.

Per Med. 2005 Nov;2(4):291-300. doi: 10.2217/17410541.2.4.291.

PMID:
29788575
32.

Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.

Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM.

Cancer Res. 2004 Dec 1;64(23):8773-7.

33.

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Camp RL, Dolled-Filhart M, Rimm DL.

Clin Cancer Res. 2004 Nov 1;10(21):7252-9.

34.

beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.

Chung GG, Zerkowski MP, Ocal IT, Dolled-Filhart M, Kang JY, Psyrri A, Camp RL, Rimm DL.

Cancer. 2004 May 15;100(10):2084-92.

35.

Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis.

Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):173-7.

37.
40.

Supplemental Content

Loading ...
Support Center